Best bets on Cleveland Clinic investments (Weekend Rounds)

Life science current events this week include a list of the best Cleveland Clinic investments, a promising wound care startup, the Tranzyme IPO and the Mayo Clinic-Charlie Sheen connection.

A review of life science current events reported by MedCity News this week:

Cleveland Clinic’s most promising startups. The return Cleveland Clinic received after the $78 million sale of Clinic spinoff Intelect Medical was the largest of three exits so far for companies affiliated with Cleveland Clinic Innovations, the health system’s technology transfer and commercialization group. But by all accounts, Cleveland Clinic has a stake in a series of promising companies and, in one case, one of the most encouraging startups in the United States.

Wound care firm Medtric pitches breakthrough bandage. Wound care startup company Medtric Biotech has developed what it says is a medical breakthrough for dressings: a bandage that both heals the wound and fights infection. Medtric says the current slate of products on the market do one or the other, but they don’t do both.

Tranzyme IPO targeted for April 4; offering re-priced at $4 per share. The company announced the date for the offering late Friday after earlier revising the terms of the IPO, lowering the target stock price to $4 per share. The Durham, North Carolina drug development company had initially planned to raise up to $65 million by selling 5 million shares in a price range of $11 to $13 per share. At a midpoint of $12 per share, Tranzyme expected net proceeds of about $53.8 million.

Mayo Clinic healthcare social media is #winning with Charlie Sheen fans. The ultimate validation of any corporate initiative is a big, fat embrace by popular culture. So chalk up another win for Mayo Clinic’s industry-leading healthcare social media program. It’s been recognized by the Charlie Sheen crowd.

Protecta FDA approval delivers new arrhythmia medical device to U.S. market. “The product launch was previously delayed as the company awaited final resolution of a warning letter from the U.S. Food and Drug Administration. The FDA had previously found problems at Medtronic’s manufacturing facility.”